MENIS, JESSICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.697
AS - Asia 141
EU - Europa 138
Totale 2.976
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.697
CN - Cina 120
IT - Italia 49
SE - Svezia 46
FI - Finlandia 22
VN - Vietnam 16
DE - Germania 7
GB - Regno Unito 6
IN - India 5
FR - Francia 3
IE - Irlanda 3
CH - Svizzera 1
UA - Ucraina 1
Totale 2.976
Salva come PNG Salva come JPEG
Città #
Fairfield 625
Ashburn 241
Woodbridge 238
Chandler 234
Cambridge 217
Seattle 216
Houston 205
Wilmington 151
Ann Arbor 84
San Diego 62
Medford 42
Princeton 42
Des Moines 38
Dearborn 35
Beijing 33
Padova 29
Helsinki 21
Ogden 18
Dong Ket 16
New York 16
Roxbury 14
Jinan 13
Nanjing 11
Nanchang 8
Shenyang 8
Boardman 6
Duncan 5
Columbus 4
Redwood City 4
Taizhou 4
Dublin 3
Jiaxing 3
London 3
Zhengzhou 3
Acton 2
Changsha 2
Guangzhou 2
Hebei 2
Pignone 2
Pune 2
Tianjin 2
Washington 2
Berlin 1
Borås 1
Hangzhou 1
Hounslow 1
Lanzhou 1
Lappeenranta 1
Milan 1
Nutley 1
Portland 1
Shanghai 1
Strasbourg 1
Treviso 1
Wuhan 1
Totale 2.681
Salva come PNG Salva come JPEG
Nome #
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 131
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer 111
Brain metastases from gastrointestinal tumours: Tailoring the approach to maximize the outcome 104
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613 104
Eribulin (Halaven): A new, effective treatment for women with heavily pretreated metastatic breast cancer 103
Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era 88
HER-2 expression in brain metastases from colorectal cancer and corresponding primary tumors: A case cohort series 87
INTEGRATED CARE PATHWAYS in LUNG CANCER: A QUALITY IMPROVEMENT PROJECT 86
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics 83
A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma 82
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy 81
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study 81
Long-term update of the 24954 EORTC phase III trial on larynx preservation 81
Prospects of targeted and immune therapies in SCLC 80
Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer 78
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation 77
Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment 76
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064) 76
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA) 75
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection 75
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: A randomized phase II EORTC trial 71
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? 70
New clinical research strategies in thoracic oncology: Clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response 70
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 68
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061) 67
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 study 65
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN) 65
Treatment duration of checkpoint inhibitors for NSCLC 63
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) 62
Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials? 61
Combination of Immunotherapy and Radiotherapy—The Next Magic Step in the Management of Lung Cancer? 61
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 60
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 59
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 57
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 56
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 55
Responding to the challenges of international collaborations between the east and the west – Report of the first JCOG–EORTC symposium and a perspective from young JCOG and EORTC investigators 52
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 52
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Results from a multicenter Italian observational study 45
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer 45
MET inhibition in lung cancer 31
Methodology of clinical trials in lung cancer 30
Totale 3.024
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.408
article - articoli 10.408
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.816
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019144 0 0 0 0 0 0 0 0 0 28 63 53
2019/2020986 45 110 18 88 118 67 99 114 163 83 49 32
2020/2021592 40 51 37 19 17 61 73 41 85 35 81 52
2021/2022706 38 73 96 56 63 42 57 56 21 19 53 132
2022/2023386 71 65 3 57 51 37 0 25 57 5 13 2
2023/2024193 9 30 24 21 12 39 20 11 25 2 0 0
Totale 3.024